Kenvue Inc. (NYSE:KVUE) Receives $25.33 Average PT from Brokerages

Kenvue Inc. (NYSE:KVUE - Get Free Report) has received a consensus recommendation of "Hold" from the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $25.33.

A number of brokerages have issued reports on KVUE. Royal Bank of Canada reissued a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Barclays boosted their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Piper Sandler raised their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Evercore ISI assumed coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target on the stock. Finally, Citigroup boosted their price target on shares of Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a research report on Friday, May 9th.

Kenvue Stock Performance

Kenvue stock traded up $0.20 during midday trading on Friday, reaching $23.93. The stock had a trading volume of 11,682,428 shares, compared to its average volume of 16,350,764. The firm has a market capitalization of $45.91 billion, a PE ratio of 45.15, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm's 50-day moving average price is $23.24 and its 200 day moving average price is $22.62. Kenvue has a 12 month low of $17.67 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Kenvue's revenue for the quarter was down 3.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.28 earnings per share. As a group, research analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date is Wednesday, May 14th. Kenvue's dividend payout ratio is currently 149.09%.

Hedge Funds Weigh In On Kenvue

Hedge funds have recently added to or reduced their stakes in the stock. Pittenger & Anderson Inc. bought a new position in shares of Kenvue during the 1st quarter worth $30,000. Geneos Wealth Management Inc. purchased a new position in Kenvue during the 4th quarter worth $29,000. SRS Capital Advisors Inc. grew its stake in shares of Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares during the last quarter. TruNorth Capital Management LLC purchased a new stake in Kenvue during the 1st quarter worth approximately $36,000. Finally, Truvestments Capital LLC purchased a new stake in shares of Kenvue during the first quarter valued at $37,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.